🇺🇸

US SEC Filing Intelligence

· daily

US Executive Compensation Proxy SEC Filings — April 30, 2026

Across 50 DEF 14A proxy statements filed around April 30, 2026, for US SEC-listed companies, overarching themes include routine director elections (avg 6-9 nominees, 80-90% independent boards), auditor ratifications for FY2026 (e.g., Deloitte, KPMG, EY dominant), and non-binding advisory votes on 2025 executive compensation with 1-year say-on-pay frequency favored. Period-over-period comp trends are mixed: 4/50 show declines (e.g., Trinity Capital CEO -50% YoY to $3.5M, Professional Diversity non-PEO avg -58% comp paid), while 2 highlight strong ties to performance (ImmunityBio 700% YoY revenue growth to $113M, Annaly 20.2% economic return). Positive outliers in biotech/health (ImmunityBio unit sales +750% YoY) and finance (Annaly 12.5% dividend yield) contrast neutral governance-focused filings; CEO transitions (Armstrong smooth handover, Grindr CFO change) and equity plan approvals signal alignment. Materiality peaks at 8-9/10 for dilution events (Contango 50% ownership shift), comp overhauls, and performance-linked pay. Portfolio implications: Biotech sector bullish on milestones, but watch comp cuts as early underperformance signals; June 2026 meeting cluster offers voting catalysts for equity expansions.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 30, 2026

Four S-1 filings on April 30, 2026, highlight a distressed IPO pipeline dominated by small-cap companies pursuing direct listings, rights offerings, and resale registrations amid weak financials and high risks. First Breach shows minimal 2025 revenues of $384k versus a $13.8M net loss with negative gross margins and working capital, lacking prior period comparisons; other filings reveal no YoY/QoQ revenue growth data but emphasize dilution from resales (GT Biopharma 9.7M shares, bioAffinity 497k shares) and deep discounts (BayFirst rights at $3.50 vs $8 close). Overarching themes include going concern doubts (2/4 companies), Nasdaq compliance pressures, and recent capital raises (BayFirst $80M preferred, GT $15.35M private placement) signaling cash desperation without dividend or buyback commitments. Sentiment skews negative/mixed (75%), with no bullish period trends or margin expansions evident. Portfolio-level implications: elevated volatility in Nasdaq Capital Market small caps; prioritize monitoring subscription success and compliance deadlines for short-term trading opportunities amid dilution overhang.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 30, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, April 30, 2026), Q1 2026 reveals robust revenue growth averaging 10-15% YoY in 70% of reporting companies (e.g., Amazon +16.6%, Alphabet +21.8%, KLA +11.5%, Glaukos +41.2%), driven by tech/services and selective industrials, but profitability is mixed with 55% showing YoY declines (avg net income drop ~20% in healthcare/industrials like Select Medical -12.7% op income, Chipotle -21.7%). Critical events dominate: takeovers/mergers (Contango ORE's 50% dilution acquisition, Select Medical $16.50/share deal closing mid-2026), credit expansions (Bob's +$75M rev line to $200M), Nasdaq compliance risks (Stardust 180-day cure), and Indian infra plays (Adani fundraising ₹15k Cr, Kajaria buyback Rs296 Cr). Capital allocation trends toward shareholder returns (buybacks in KLA $1.72B 9M, Chipotle $755M Q1; divs in Ford $0.15/shr) amid capex surges (Amazon +76.7% to $44B). Sector patterns: Tech outperforms (avg rev +20%), healthcare mixed on M&A/legal costs, autos/rail cautious on cash flow. Portfolio implications: Favor large-cap growth (Amazon/Alphabet), monitor small-cap risks/delisting, alpha in post-merger catalysts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 30, 2026

Across 50 Q1 2026 10-Q filings, revenues showed resilience with 32/50 companies reporting YoY growth averaging +12% (outliers like Glaukos +41.2%, Amazon +16.6%), though margins compressed in 28/50 (avg -150bps) due to rising opEx, labor, and R&D. Net income was mixed: 24 firms swung to or improved profitability (e.g., Amazon +76.7%, PBF turnaround from loss), but 26 posted widening losses, especially biotechs (Viking -3x, Cartesian -121%). Capital allocation emphasized returns with 22/50 executing buybacks (total ~$5B+, e.g., Chipotle $755M, KLA $1.72B 9M) and 18 raising/increasing dividends (e.g., NorthWestern +2%, InterDigital +17%). Cash flows improved operationally in 30/50 (avg +25% YoY), but high capex ($10B+ aggregate) and debt rises flagged balance sheet strains. Sector themes highlight tech strength (Alphabet +21.8% rev), auto recovery (Ford +6.4%), biotech cash burn, and energy volatility; actionable now: favor revenue growers with buybacks amid mixed sentiment (44/50 mixed). Portfolio implication: overweight tech/large caps with strong FCF, monitor biotechs for catalysts.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — April 30, 2026

Across four 8-K filings in the USA Trading Suspensions stream, small-cap Nasdaq-listed companies face mounting compliance pressures, with 3/4 (Elite Express, Stardust Power, American Resources) receiving deficiency notices for bid price, market value/listed securities (MVLS), equity/net income, and late 10-K filing, but all granted cure periods extending to October 2026 with no immediate trading halts or delistings. Innventure stands out positively with board refresh appointing operations and finance experts amid shareholder engagement, contrasting sector governance strains. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity reported across filings, limiting quantitative growth insights, though forward-looking compliance deadlines create a catalyst calendar clustered in Q3/Q4 2026. Capital allocation details absent, but operational highlights like Stardust's Lithium Refinery Project support signal potential turnaround paths. Portfolio-level pattern: emerging growth companies vulnerable to Nasdaq rules 5550/5250, implying heightened delisting risk and volatility; investors should prioritize monitoring for cure success amid mixed/negative sentiment (avg materiality 8.25/10). Market implications include short-term trading stability but elevated long-term suspension risks, favoring defensive positioning.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 30, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (41 new), the dominant theme is corporate resilience through aggressive debt refinancing, facility expansions, and capital raises, with 12+ companies amending/extending credit lines (e.g., FTAI Aviation's $2.025B oversubscribed facility up from $400M) amid few outright bankruptcies but notable Nasdaq compliance failures. Period-over-period trends show mixed revenue (e.g., Martin Marietta +17% YoY to $1.36B, ProPetro -7% QoQ to $271M) and profitability (e.g., Tiptree EPS +162% YoY to $0.34, BayFirst net loss widened to $5.7M QoQ), with EBITDA pressures in energy (ProPetro -29% QoQ) offset by strong cash flows (Martin Marietta ops cash record $227M). Capital allocation leans toward deleveraging (FTAI Infra selling for $1.52B to repay $300M debt) and shareholder returns ($251M Martin Marietta Q1). Forward-looking catalysts cluster in Q3 2026 (M&A closings like ACRES/ACC, MARA/Long Ridge), signaling potential turnarounds, though Nasdaq delistings/threats (5 cases) and covenant waivers (Trinseo) flag ongoing distress risks. Portfolio-level, real estate/finance sectors show 8/10 amendments positive for liquidity, while small caps face equity dilution from raises. Implications: Buy dips in refinancing winners, short Nasdaq laggards; alpha in accretive M&A.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — April 30, 2026

Across 43 filings in the USA Executive & Director Changes stream (40 new since last brief), the dominant theme is a surge in C-suite transitions, with 18 CFO/CEO/President appointments or changes (e.g., Entegris, Eos Energy, ResMed, Teleflex, Nexgel, Amtech, Red Robin, Halozyme) and 12 retirements/resignations/transitions (e.g., Matrix Service, NeuroOne, Marcus Corp, Recursion founder), signaling proactive leadership refreshes amid stable-to-growing operations. Period-over-period trends where reported show revenue growth averaging +8.7% YoY (Kirby +7.5%, CCC +12%, Select Medical +5%, ResMed gross margins 62-63% reiterated), but mixed margins (Kirby distribution -60 bps to 6.7%, Select op income -12.7% YoY). Annual meetings (12 filings) overwhelmingly passed director elections (>90% approval avg), equity plan expansions (e.g., Chemours +6.4M shares, RLJ +4.8M), and say-on-pay, with positive sentiment in 65% of filings. Capital allocation leans shareholder-friendly: dividends maintained/declared (BorgWarner $0.17, Select $0.0625, Kirby $52.7M buyback), buybacks (Teleflex $1B), no cuts noted. No widespread insider selling; equity grants/RSUs common (Vuzix CEO 477k RSUs). Implications: Bullish for sectors like healthcare/tech with experienced hires boosting execution, watch small caps for transition risks, portfolio-level alpha from pre-close catalysts like Q1 10-Qs and May-June starts.

43 high priority 43 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 30, 2026

Across 43 SEC filings on USA Board Room Changes from April 2026, a dominant theme is high CFO turnover with 15+ appointments or transitions (e.g., Entegris, Eos Energy, ResMed, NEXGEL), often featuring executives with 20-30+ years experience from blue-chip firms like Medtronic, J&J, signaling strategic upgrades amid growth pivots. Annual shareholder meetings (12+ filings) showed robust support for director elections (avg 95%+ FOR), equity plans, and say-on-pay, underscoring board stability. Period-over-period trends mixed: revenue growth in 4/6 reporting firms (CCC +12% YoY, Kirby +7.5% YoY, Select Medical +5% YoY), but margins compressed (Kirby distribution -60 bps YoY, Select ops income -12.7% YoY). Positive sentiment prevails (25/43 filings), with capital allocation supportive (Kirby $52.7M buybacks, BorgWarner $0.17 div, Select $0.0625 div). Implications: Bullish for healthcare/tech leadership refreshes, watch energy/industrials for transition risks; portfolio trend toward stronger governance boosting M&A appeal.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — April 30, 2026

Across 9 US M&A filings on April 30, 2026, a surge in transaction completions dominates, with 4 divestitures generating ~$2.4B in cash proceeds (SM Energy $950M, Spire $215M, Perrigo €306M net, Golden $2.75/share dividend), funding debt reduction, redemptions, and acquisitions amid portfolio streamlining. Positive sentiment prevails in 5/9 cases (SM Energy, Spire, Perrigo, Plutonian SPAC IPO, Bakkt acquisition), contrasting mixed/neutral in mergers involving dilutions or spin-outs (Golden, SOBR Safe 98% dilution, Coeptis pro forma op loss worsening YoY). Period comparisons highlight Coeptis Therapeutics' pro forma 2025 net loss improvement to $(9.1M) from $(12.3M) but operating loss deterioration to $(10.0M) from $(5.1M) YoY, signaling persistent unprofitability post-spin-out. SPAC activity intensifies with Plutonian's $100M IPO and SIM's deadline extension to 2027, while energy firms (SM, Spire) advance $1B+ divestiture targets. Capital allocation trends favor debt deleveraging (SM $819M notes redemption, Perrigo debt reduction) over dividends/buybacks, implying fortified balance sheets but limited shareholder returns. Market implications include alpha from post-M&A catalysts like redemptions and approvals, with watch for Q3 2026 closings amid high materiality (avg 8.7/10).

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 30, 2026

Across 50 overnight SEC filings for Q1 2026, overarching themes include robust revenue growth averaging ~10-15% YoY in tech giants (Amazon +16.6%, Alphabet +21.8%, KLA +11.5%) and select healthcare (Glaukos +41.2%, ImmunityBio +700%), contrasted by widespread margin compression and operating losses in industrials (Pilgrims Pride op inc -59.8%, Titan op loss on impairments), consumer (Chipotle NI -21.7%), and healthcare (Anika op loss +28%). Capital allocation leans shareholder-friendly with buybacks (Amazon none but prior, News Corp $1B program, KLA $1.72B), dividends (Ford cut to $0.15, NorthWestern +2%), and repurchases across banks (First Northern 6%, Southside none in Q1). Mixed sentiments dominate (28/50 mixed), but positive outliers signal resilience in cloud/AI (Alphabet Cloud +63.4%) and insurtech turnarounds (Hippo NI positive vs prior loss). SPAC post-IPO losses (QDRO, RF Acquisition) and shelf registrations (Veradermics +$57M, Vivos pivot) highlight fundraising amid going concern risks. Portfolio-level trends show QoQ cash declines in 12/20 Qs, but op cash improvements in 8/15, implying capex/reinvestment pressures; watch earnings calls today (Pilgrims, CIMPRESS) for guidance clarity.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 29, 2026

The April 29, 2026 period recorded 1 FDA approval in the Biotech Small-Cap stream: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other. Alembic's FINGOLIMOD HYDROCHLORIDE received fallback approval, noted as a biosimilar in summary but categorized as other, delivering a neutral signal (strength 5/10, materiality 5/10) with all commercial metrics NOT_DISCLOSED. No dominant therapeutic area theme emerges from this lone approval, likely in neurology/MS given the drug's profile. The highest-conviction signal is Alembic's neutral market entry for FINGOLIMOD HYDROCHLORIDE, posing limited upside for the entrant while flagging mild competitive pressure on originator Novartis' Gilenya. Key risk/watch item is originator revenue erosion risk upon Alembic launch, balanced against unknown entrant pricing power.

1 total filings
· daily

New Drug Approvals (Original) — April 29, 2026

The FDA issued 1 approval from April 29 to April 29, 2026, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other. ALEMBIC's FINGOLIMOD HYDROCHLORIDE represents a fallback approval, delivering a neutral investment signal (strength 5/10, materiality 5/10) with no disclosed peak sales, exclusivity, pricing, or market position data. No dominant therapeutic area theme emerges from this lone approval. The highest-conviction signal is ALEMBIC's FINGOLIMOD HYDROCHLORIDE approval, implying modest entry potential in an established market without near-term catalysts. Key risk/watch item: Lack of commercial transparency (all metrics NOT_DISCLOSED) warrants monitoring for launch execution risks.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 29, 2026

HHS awarded a single $92,501,232 cost-sharing contract to Basilea Pharmaceutica International Ltd (parent: Basilea Pharmaceutica AG) via BARDA, representing 100% civilian healthcare R&D funding with zero defense exposure. This full and open competition award for antimicrobials R&D against resistant fungal and bacterial infections provides long-term revenue visibility through 2031 (or potentially 2035), with only $36.2M outlayed to date and annual estimates of $13.2M (base) to $24.3M (full options). The highest-conviction bullish signal is the $267.6M ceiling potential, signaling BARDA's commitment to health preparedness. Key watch item: progress on option exercises and performance milestones amid R&D execution risks.

1 total filings
· daily

New Federal Contractors — April 29, 2026

These three new federal contracts totaling $259,112,045 in obligations are entirely civilian (0/3 defense-related), spanning NASA, HHS/BARDA, and Department of State with an average signal strength of 5.7/10. The dominant theme is long-duration R&D and IT services in health preparedness and national security support, led by Basilea Pharmaceutica International Ltd's $92.5M BARDA award for antimicrobials R&D—the highest-conviction bullish signal due to its $267.6M ceiling and 7-11 year horizon. Neutral signals dominate from historical LJT & Associates ($94.6M NASA, ended 2019 with low $8.8M outlay) and ongoing Idemia National Security Solutions ($72M State Dept, $18.2M outlayed through 2026). Key risk: stalled outlays on LJT and Idemia signal execution hurdles; watch Basilea option exercises toward $267.6M.

3 total filings
· daily

Significant Contract Modifications ($10M+) — April 29, 2026

These three significant contract modifications total $259,112,045 in obligations, entirely civilian with zero defense-related awards across NASA, HHS/BARDA, and Department of State. Dominant themes include health preparedness R&D, historical space launch operations, and ongoing facial recognition IT integration. The highest-conviction signal is bullish for Basilea Pharmaceutica International Ltd's $92.5M BARDA award for antimicrobials R&D, offering multi-year revenue potential up to $267.6M ceiling through 2035. Neutral signals dominate for LJT & Associates ($94.6M NASA, low outlays) and IDEMIA National Security Solutions ($72M State Dept, partial funding). Key watch item: option exercises and outlay progress across all, given low disbursements relative to obligations (e.g., only $8.8M outlaid on LJT's $94.6M).

3 total filings
· daily

Contract Deobligations Alert — April 29, 2026

This Contract Deobligations Alert covers $259,112,045 in total obligations across three civilian contracts from NASA, HHS/BARDA, and the Department of State, with zero defense-related awards. The dominant theme is long-duration civilian R&D and IT services, highlighted by Basilea Pharmaceutica International Ltd's $92.5M bullish BARDA award for antimicrobials R&D against resistant infections, offering the highest-conviction growth signal with potential upside to $267.6M ceiling through 2035. Neutral signals dominate from historical LJT & Associates' $94.6M NASA launch support contract (ended 2019 with minimal $8.8M outlay) and ongoing Idemia National Security Solutions LLC's $72M State Department facial recognition integration (partial $18.2M outlay to 2026). A key risk is low outlay pacing across all contracts, signaling potential deobligation or execution hurdles. Investors should watch BARDA option exercises for Basilea as the primary near-term catalyst amid civilian agency priorities.

3 total filings
· daily

Contract Option Exercises — April 29, 2026

These three contract option exercises total $259,112,045 in obligations, entirely civilian with zero defense-related awards across NASA, HHS/BARDA, and Department of State. The dominant theme is long-duration civilian R&D and support services in health preparedness, space operations, and IT security, highlighted by a highest-conviction bullish signal on Basilea Pharmaceutica International Ltd's $92.5M HHS/BARDA award for antimicrobials R&D amid resistant infections. Neutral signals dominate for LJT & Associates ($94.6M NASA, historical with low outlays) and IDEMIA National Security Solutions ($72M State Dept, partial funding). Key watch item: progress on option exercises and outlays, especially Basilea's path to $267.6M ceiling through 2035.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — April 29, 2026

The analyzed contracts total $72,032,459 in obligations, representing a fully civilian award with 0/1 defense-related, centered on the Department of State's ACQUISITIONS - AQM MOMENTUM office. IDEMIA NATIONAL SECURITY SOLUTIONS LLC secured a firm fixed price delivery order for facial recognition system integration with visa and passport processes, offering multi-year revenue visibility through 2026-09-29 but with only $18,176,969 outlayed to date. The highest-conviction signal is neutral (6/10 strength), highlighting steady operational support revenue in Federal IT & Cybersecurity without defense exposure. A key risk is high pricing risk on the firm fixed price structure, potentially pressuring margins if costs overrun.

1 total filings
· daily

All HHS Contracts — April 29, 2026

HHS obligated $92,501,232 across 1 contract during the period, representing 100% civilian spending with 0 defense-related awards. The dominant theme is BARDA-funded R&D for antimicrobials targeting resistant fungal and bacterial infections, led by a single high-materiality award to Basilea Pharmaceutica International Ltd (parent: Basilea Pharmaceutica AG). This delivers the highest-conviction bullish signal via long-term cost-sharing funding under full and open competition, with only $36,222,783 outlayed to date against a potential $267,582,260 ceiling including options. Annual revenue potential is estimated at ~$13.2M/year through 2031 or ~$24.3M/year if fully realized to 2035. Key watch item: progress on option exercises and performance milestones amid R&D execution risks.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 29, 2026

Three high-value civilian federal contracts totaling $259,112,045 obligation (0/3 defense-related) highlight diverse non-defense spending: NASA's $94.6M historical award to LJT & Associates for space launch support (neutral signal), HHS/BARDA's $92.5M bullish R&D grant to Basilea Pharmaceutica International Ltd for antimicrobials, and State Department's $72.0M ongoing IT delivery order to IDEMIA National Security Solutions LLC for facial recognition integration. Dominant sector theme is civilian R&D and tech services, with BARDA health preparedness as the standout. Highest-conviction signal is bullish long-term funding for Basilea ($92.5M obligated, potential $267.6M ceiling to 2035). Key risk is low outlay progress across contracts (e.g., only $8.8M of LJT's $94.6M and $36.2M of Basilea's $92.5M disbursed), warranting watches on option exercises and performance milestones.

3 total filings